BELLY BLISS
Food supplement declared in France, declaration No 2024-6-1533, decision dated 27 June 2024
BELLY BLISS (Yfen) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Fucus vesiculosus 200 mg per day, Paullinia cupana 30 mg per day, Capsicum annuum 22.5 mg per day, Lactobacillus Plantarum Lp90 1,500,000,000 (unit not declared) per day, Lacticaseibacillus Rhamnosus LRa05 1,500,000,000 (unit not declared) per day. None of the rules we check flags an issue with its declared composition.
- Brand
- Yfen
- Food business operator placing the product on the market
- BEAUTY BLEND
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 2 gélules par jour
- Directions for use
- Prendre 2 gélules par jour pendant 1 mois
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Kidney stones, Children (under 12), Young children (aged 1 to 3), Pregnant women, Kidney failure, Kidney disease, Heart problems, Taking anticoagulants, Taking thyroid medication, Ulcer (stomach or duodenum), Children (under 6), Children (under 10)
- Objectives stated by the manufacturer (these are not authorised claims)
- Slimming / Flat stomach
Declaration 143228, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Fucus vesiculosus L. | Thalle | Extrait sec hydroalcoolique | 200 mg |
| Paullinia cupana Kunth | Graine | Extrait sec hydroalcoolique | 30 mg |
| Capsicum annuum L. | Fruit | Poudre (de plantes séchées ou broyées) | 22.5 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Charbon végétal | not declared |
Micro-organisms
| Strain | Per day |
|---|---|
| Lactobacillus Plantarum Lp90 | 1,500,000,000 (unit not declared) |
| Lacticaseibacillus Rhamnosus LRa05 | 1,500,000,000 (unit not declared) |
| Lactobacillus Paracasei LC86 | 1,500,000,000 (unit not declared) |
| Bifidobacterium Bifidum BBi32 | 1,500,000,000 (unit not declared) |
| Bifidobacterium Lactis BLa80 | 1,500,000,000 (unit not declared) |
Other ingredients
Gélule végétale, poudre de cacao maigre
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Ne pas dépasser la portion journalière. Ne se substitue pas à un régime alimentaire varié et un mode de vie sain. Tenir hors de la portée des jeunes enfants. Tenir à l’abri de la lumière, de la chaleur et de l’humidité. Réservé aux adultes. Déconseillé aux femmes enceintes ou allaitantes. Déconseillé en cas de pathologies cardiaques, rénales, thyroïdiennes ou d’ulcère gastro-duodénal. L'emploi chez les personnes sous traitement anti-coagulant est déconseillé. En cas de traitements médicamenteux, demander conseil à un professionnel de santé. Consommer le complément alimentaire à distance de médicaments (au moins 60 minutes d’intervalle).
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Capsicum annuum L.
Read the warning, when it applies and the studies cited
CAYENNE - CAPSICUM ANNUUM Oral
Cautions and warnings
Condition of application: All products.
Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).
Sources cited by Health Canada (2)
- Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).
Sources cited by Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Condition of application: Digestion; Peripheral circulation.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 March 2026
CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical
Cautions and warnings
Condition of application: All products.
For external use only (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Known adverse reactions
Condition of application: All products.
Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).
Sources cited by Health Canada (5)
- APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
- Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
- McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Randomised trial
- Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Systematic review
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : Yfen
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “BELLY BLISS (Yfen): composition and regulation”, https://compoatlas.com/en/supplements/products/143228-belly-bliss, updated 15 November 2026.